^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ATA2271

i
Other names: ATA2271, M28z1XXPD1DNR CAR T cells, ATA 2271, ATA-2271
Associations
Company:
Memorial Sloan-Kettering Cancer Center
Drug class:
Mesothelin-targeted CAR-T immunotherapy
Associations
1m
New P1 trial
|
ATA2271
4ms
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma (clinicaltrials.gov)
P1, N=14, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=30 --> 14
Enrollment closed • Enrollment change • CAR T-Cell Therapy • Checkpoint inhibition
|
MSLN (Mesothelin)
|
cyclophosphamide • ATA2271
5ms
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma (clinicaltrials.gov)
P1, N=30, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Checkpoint inhibition
|
MSLN (Mesothelin)
|
cyclophosphamide • ATA2271
1year
Tumor-targeted non-ablative radiation promotes solid tumor CAR T-cell therapy efficacy. (PubMed, Cancer Immunol Res)
We use a nonablative dose of tumor-targeted radiation prior to systemic administration of mesothelin-targeted CAR T cells to assess infiltration, proliferation, antitumor efficacy, and functional persistence of CAR T cells at primary and distant sites of tumor...Our results strongly suggest that the use of tumor-targeted radiation prior to systemic administration of CAR T cells may substantially improve CAR T-cell therapy efficacy for solid tumors. Building on our observations, we describe a translational strategy of "sandwich" cell therapy for solid tumors that combines sequential metastatic site-targeted radiation and CAR T cells-a regional solution to overcome barriers to systemic delivery of CAR T cells.
Journal • CAR T-Cell Therapy • IO biomarker
|
MSLN (Mesothelin)
|
MSLN expression
|
ATA2271
almost2years
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma (clinicaltrials.gov)
P1, N=30, Recruiting, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Recruiting | Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
Enrollment open • Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Checkpoint inhibition
|
MSLN (Mesothelin)
|
MSLN expression
|
cyclophosphamide • ATA2271
over2years
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma (clinicaltrials.gov)
P1, N=7, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=30 --> 7
Enrollment closed • Enrollment change • CAR T-Cell Therapy • Checkpoint inhibition
|
MSLN (Mesothelin)
|
MSLN expression
|
cyclophosphamide • ATA2271
3years
Promoting Functional Persistence in Solid Tumor CAR T-cell Therapy: Mesothelin-targeted CAR (M28z1XXPD1DNR) with T-cell Intrinsic PD1 Dominant Negative Receptor (ESMO-IO 2021)
Clinical safety and systemic persistence of M28z1XXPD1DNR CAR T cells was investigated in 4 pleural mesothelioma patients (NCT04577326)...Legal entity responsible for the study Memorial Sloan Kettering Cancer Center. Funding ATARA Biotherapeutics.
CAR T-Cell Therapy
|
MSLN (Mesothelin)
|
ATA2271
over3years
A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. (PubMed, Cancer Discov)
Stable disease was sustained for {greater than or equal to}6 months in 8 patients; 2 exhibited complete metabolic response on PET scan. Combination immunotherapy with CAR T cells and PD-1 blockade agents should be further evaluated in patients with solid tumors.
Clinical • P1 data • Journal • Combination therapy • CAR T-Cell Therapy
|
MSLN (Mesothelin)
|
Keytruda (pembrolizumab) • ATA2271
over3years
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma (clinicaltrials.gov)
P1, N=30, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Sep 2022 --> Sep 2023 | Trial primary completion date: Sep 2022 --> Sep 2023
Clinical • Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Checkpoint inhibition
|
MSLN (Mesothelin)
|
MSLN expression
|
ATA2271 • cyclophosphamide intravenous
5years
Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients (ASH 2019)
Median number of prior therapies was 1, including 8 pts w/ previous allogeneic hematopoietic cell transplant (alloHCT) and 5 w/ prior chimeric antigen receptor T-cell therapy (CAR-T)...One pt w/ grade 2 CRS received tocilizumab for hypotension suboptimally responsive to fluid boluses (FB) w/ IL-6 level = 25754 pg/mL...Peak APR levels correlated w/ CRS severity. Authors noted concordance of CRS grading between CTCAE and ASTCT, suggesting the feasibility of a single, BITE-specific grading system.
Clinical • Real-World Evidence • IO biomarker
|
IL6 (Interleukin 6) • CRP (C-reactive protein)
|
Blincyto (blinatumomab) • Actemra IV (tocilizumab) • ATA2271 • CAR T-cell therapeutics
5years
Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells (ASH 2019)
Methods We analyzed 2 different populations of adult CAR T cells pts treated at our institution: 1) B-cell acute lymphoblastic leukemia (B-ALL) pts treated with CD1928z CAR T cells from 2010 to 2016 (NCT01044069), and 2) aggressive diffuse large B-cell lymphoma (DLBCL) pts treated with axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) after FDA approval starting from 2018...Moreover, both high EASIX and mEASIX scores on day +1 and day +3 are associated with occurrence of grade ≥3 CRS and grade ≥3 ICANS, respectively. We conclude that EASIX and mEASIX, as markers of endothelial damage and inflammation, could be useful as early predictors in guiding treatment decisions before the onset of severe symptoms.
Clinical • CAR T-Cell Therapy
|
IL6 (Interleukin 6)
|
Yescarta (axicabtagene ciloleucel) • Kymriah (tisagenlecleucel-T) • ATA2271